Jacobson Pharma Corporation Limited (HK:2633) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jacobson Pharma Corporation Limited reported a robust financial performance for the six months ending September 2024, with a 13.3% increase in revenue to HK$810.0 million and a 44.2% surge in profit from continuing operations to HK$140.3 million. The company also declared a 40% higher interim dividend, reflecting strong growth compared to the same period in 2023. These results highlight the company’s resilient business model and its promising outlook for investors.
For further insights into HK:2633 stock, check out TipRanks’ Stock Analysis page.